Kailera Therapeutics, Inc.
KLRANASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $1.31B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $9.76$28.23
- Volume (live)
- -
- Avg. volume (3M)
- 1.41M
Kailera Therapeutics (KLRA) Stock Price & Financial Analysis
Kailera Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $12.62 - $13.14 |
|---|---|
| 52-Week High | $28.23 |
| 52-Week Low | $9.76 |
| Open | $12.85 |
| Volume (last close) | 589.40K |
| Average Volume (3M) | 1.41M |
| 50-Day MA | $14.11 |
|---|
| Market Cap | 1.31B |
|---|---|
| Shares Outstanding | 102.23M |
| Price to Book (P/B) | 1.17 |
| EV/EBITDA | -4.81 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Kailera Therapeutics at a Glance
As of the Oct 26, 2026 close, Kailera Therapeutics (KLRA) has a market capitalization of $1.31B.
As of its latest reported balance sheet, it holds $130.30M in cash and securities against $10.22M of debt, a net cash position of $120.08M.
Kailera Therapeutics does not currently pay a dividend.
At $12.77 (the Oct 26, 2026 close) it sits within its 52-week range of $9.76 to $28.23.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $45.00, 252.4% above the Oct 26, 2026 close.
Frequently Asked Questions About Kailera Therapeutics
What is the current stock price for KLRA?
As of the Oct 26, 2026 close, KLRA stock trades at $12.77. The 52-week range is $9.76–$28.23, with a day range of $12.62–$13.14.
What is the P/E ratio for KLRA?
The P/E ratio (Price-to-Earnings) for KLRA is shown in the Key Statistics section. This valuation metric helps compare Kailera Therapeutics, Inc. to industry peers.
Does KLRA pay dividends?
Kailera Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for KLRA?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for KLRA is Buy. The average 12-month price target is $45.00, a 252.4% upside from the Oct 26, 2026 close of $12.77.
What is the market cap of KLRA?
As of the Oct 26, 2026 close, Kailera Therapeutics's market capitalization is $1.31B, classifying it as a small-cap company. Kailera Therapeutics operates in the Healthcare sector within the Biotechnology industry.